Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A role for collagen XXIII in cancer cell adhesion, anchorage-independence and metastasis.

Oncogene·2011
Same author

miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo.

Oncogene·2011
Same author

Antizyme, a mediator of ubiquitin-independent proteasomal degradation and its inhibitor localize to centrosomes and modulate centriole amplification.

Oncogene·2007
Same author

Hold that line. Angiomotin regulates endothelial cell motility.

The Journal of cell biology·2001
Same author

Molecular cloning and structural characterization of the rat thymosin beta15 gene.

Gene·2001
Same author

C-terminal variations in beta-thymosin family members specify functional differences in actin-binding properties.

Journal of cellular biochemistry·2000

Related Experiment Video

Updated: Jun 26, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Angiogenesis and tumor metastasis

B R Zetter1

  • 1Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. zetter@a1.tch.harvard.edu

Annual Review of Medicine
|March 24, 1998
PubMed
Summary

New blood vessel formation, or angiogenesis, is crucial for cancer metastasis. Targeting angiogenesis with inhibitors offers a promising, less toxic cancer treatment strategy currently in clinical trials.

Area of Science:

  • Oncology
  • Vascular Biology
  • Cancer Metastasis

Background:

  • Angiogenesis, the formation of new blood vessels, is vital for tumor growth and metastasis.
  • Tumor vascularity is a prognostic indicator of metastatic potential.
  • Tumor cells utilize newly formed blood vessels to enter circulation and metastasize.

Purpose of the Study:

  • To review the role of angiogenesis in cancer metastasis.
  • To discuss the regulation of tumor angiogenesis by stimulators and inhibitors.
  • To explore the therapeutic potential of anti-angiogenic agents in cancer treatment.

Main Methods:

  • Review of scientific literature on angiogenesis and cancer metastasis.
  • Analysis of the mechanisms regulating tumor angiogenesis.

More Related Videos

Isolation and Culture Expansion of Tumor-specific Endothelial Cells
10:15

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Published on: October 14, 2015

Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis
09:42

Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis

Published on: June 26, 2019

Related Experiment Videos

Last Updated: Jun 26, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Isolation and Culture Expansion of Tumor-specific Endothelial Cells
10:15

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Published on: October 14, 2015

Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis
09:42

Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis

Published on: June 26, 2019

  • Examination of clinical trial data for anti-angiogenic therapies.

    • Main Results:

    • Tumor vascular density correlates with metastatic potential.
    • Fibroblast growth factors and vascular endothelial growth factors stimulate angiogenesis.
    • Angiostatin and endostatin are examples of angiogenesis inhibitors.
    • Anti-angiogenic agents show potential for reduced toxicity and drug resistance compared to cytotoxic drugs.

    Conclusions:

    • Angiogenesis is a critical target for anti-cancer therapy.
    • Anti-angiogenic agents represent a promising new class of cancer drugs.
    • Ongoing clinical trials aim to optimize anti-angiogenic treatment strategies.